SMALL CAP IDEA: 'Neuro-psych' specialist Solvonis emerges in takeover wave
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
Frontiers4d
Editorial: Alternative treatments to classical antidepressants in treatment-resistant depression
In recent years, there has been particular interest in the antidepressant effects of ketamine in patients with TRD. Ketamine is a racemic mixture of two enantiomers, R- and S-ketamine, with the latter ...
pharmaphorum6d
J&J builds case for antidepressant Spravato with head-to-head trial
an intranasal formulation of racemic ketamine. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
Frontiers4d
The Pharmacology of Visual Hallucinations in Synucleinopathies
Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the ...